Join Us | Become a Member
Get In Touch
619.804.2089
Follow Us
Sorted by
Newest posts Popular Latest activity
Marcille Pilkington
Marcille Pilkington
  in  â›°ď¸Ź arts-2026
August 06

He's been an orthopedic surgeon for 20 years. This weekend surprised him.

Dr. Allan Mishra — Stanford faculty, regenerative medicine researcher, host of Vitality Explorers — joined us as faculty at the 2026 ARTS Summit at Torrey Pines. He went home and recorded a whole episode on what he hadn't known: that fat isn't inert storage, but living, reparative tissue richer in stem and signaling cells than bone marrow.

We wrote him back on The Regenerative Current — on the science, and on why we're also exploring what it means to care for the caregiver, not just the patient.

Read it → Read Substack Article
Ramon Llull, MD, PhD
Ramon Llull, MD, PhD
  in  đź§­ trc
July 23

A Personal Invitation to Shape the Language of Regenerative Medicine

I purposely wish to extricate myself from being an initiator of the Tissue Response Compass (TRC). Much rather,  I would like to extend a personal invitation to my colleagues and friends around the world—physicians, surgeons, scientists, researchers, educators, trainees, regulators, and industry partners—to participate in the ongoing development of this resource. The concepts and definitions presented herein are not intended to represent a final authority, but rather a starting point for discussion, refinement, and collective advancement. Regenerative medicine is evolving at an extraordinary pace, and our language must evolve with it. New discoveries continually challenge existing paradigms, while emerging technologies introduce concepts that often lack clear and universally accepted definitions. It is therefore essential that the vocabulary guiding our field be developed collaboratively, transparently, and with scientific rigor.

This document fully acknowledges and reflects my own experiences, interpretations, and biases. In truth, it is impossible to separate oneself from the lens through which one observes science. Some definitions may resonate immediately, while others may provoke disagreement. I welcome both reactions. In fact, certain concepts have been intentionally framed to stimulate debate, encourage critical thinking, and expose areas where consensus remains elusive. Constructive controversy has long been a catalyst for scientific progress.

My hope is that the TRC becomes a living, community-driven resource that grows through your contributions. I encourage you to challenge existing terminology, propose new definitions, introduce emerging concepts, and identify gaps that deserve attention. Together, we can build a common language that strengthens communication, improves education, accelerates innovation, and ultimately advances the science and practice of regenerative medicine for the benefit of patients worldwide.

Ramon Llull, MD, PhD
Robert Alexander, MD, DMD, FICS
Robert Alexander, MD, DMD, FICS
  in  đź”¶ general
July 14
• Edited (Jul 23, 2026)

Colleagues & Friends,

Very glad that many of you were able to attend the full session at the 2026 ARTS Summit — this new COMMONS community is the perfect place to extend the conversation among devoted individuals who contribute to Regenerative Medicine evolution.

The heart of last year and this year’s presentation is simple: we can't call a treatment OR define an outcome as a direct result or actual "evidence". If we never work to measure what we delivered, the information may be valid but not reproducible by others (or yourself). AD-tSVF and HD-PRP are deployed every day, yet the cell content (numbers, viability, size) and platelet concentration (baseline and concentrate ACTUALLY attained are rarely tested or recorded. Without that documented cellular and biological blood derivative, an outcome is just an anecdote. You do not have to become a Clinical Trial site to be able to determine what the patients received and correlate their course and outcomes. Over time, these, along with standardization and clarity of vocabulary, will lead you to creating valuable data for the future.

Those who know me realize that I believe strongly in the value of centrifugation of the tSVF harvested for key important reasons. Use of a devoted, multipurpose, small, programmable centrifuge is now becoming a reality. This, paired with a point-of-care counting for cells, plus a simple hemocytometer to determine baseline-actual achieved platelet count, can become a measurement platform — so we all can finally connect dose to response, patient by patient, and report in publications and presentations to audiences who know the why and how.

ARTS has provided the following links should you wish to review information or content: